Develops and markets veterinary diagnostic instruments. Offers blood chemistry and hematology analyzers for in-clinic use. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 19% a year on average.
Sales run at $257.3M a year. A small number, but proof the product has real buyers.
There is $156.6M in the vault; even if every debt were paid off, $53.5M would remain.
A loss of $18.4M against $257.3M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.